Japan-based KM Biologics, a group company of Meiji Seika Pharma, has entered into a technology collaboration with Serum Institute of India, the world's largest vaccine manufacturer, for the development and manufacturing of a Japanese encephalitis vaccine targeting stable large-scale supply in India, according to Bio Spectrum Asia.

The collaboration is based on a technology transfer agreement between KM Biologics and Pune-based Serum Institute of India, a Cyrus Poonawalla group company. With the achievement of the first milestone under the agreement, Serum Institute of India will initiate development activities in India for the Japanese encephalitis vaccine currently manufactured and marketed by KM Biologics.

Japanese encephalitis remains a significant public health challenge across Asia and a major infectious disease concern in India, where strong demand exists for stable, large-scale vaccine supply under the national immunisation programme.

The two companies will work closely to advance development and establish manufacturing and supply by Serum Institute of India, leveraging its position as one of the world's largest vaccine manufacturing operations alongside KM Biologics' expertise in vaccine research, development, and quality control.

Meiji Seika Pharma has positioned contributing to global infectious disease control as a key mission, and is actively expanding its business across Global South markets. The collaboration with Serum Institute of India is expected to serve as an important foundation for future business development across Asia.

Through the partnership, both companies aim to strengthen public health outcomes by ensuring reliable access to Japanese encephalitis vaccines for populations across India and the broader Asia-Pacific region.

Access the full report for further detail on the KM Biologics and Serum Institute of India collaboration.